{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of CI was not achieved due to low number of participants with event.","groupId":"OG000","lowerLimit":"11.6","upperLimit":"NA","value":"14.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"DOR was defined as the duration from the first tumor assessment that supports the participant's objective response (CR or PR, whichever is first recorded) to disease progression or death due to any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered atezolizumab intravenously on Day 1 of each 21 day cycle at a fixed dose of 1200 mg. Atezolizumab treatment were to continued as long as participants were experiencing clinical benefit as assessed by the investigator.","id":"OG000","title":"Atezolizumab"}],"paramType":"MEDIAN","populationDescription":"ITT population for efficacy analyses included all randomized participants, regardless of whether they received any study drug. Here, number of participants analyzed signifies the number of participants who were evaluable for this outcome measure. The data was planned to be reported for Atezolizumab arm only.","reportingStatus":"POSTED","timeFrame":"From the time of randomization to the date of death due to any cause or up to data cut off date: 08 May 2015 (up to 21 months)","title":"DOR (Modified RECIST)","type":"SECONDARY","unitOfMeasure":"months"}